TLR-4 and CD14 Genotypes and Soluble CD14: Could They Predispose to Coronary Atherosclerosis?

Area of Science:

• Immunogenetics
• Cardiovascular Disease Research

Background:

• Atherosclerosis pathogenesis involves inflammatory mechanisms.
• Investigates functional polymorphisms of Toll-like receptor 4 (TLR-4) and CD14 in Coronary Artery Disease (CAD).

Purpose of the Study:

• To analyze the association between TLR-4 (Asp299Gly, Thr399Ile) and CD14 (C260T) polymorphisms and plasma soluble CD14 levels with CAD.
• Determine the role of these genetic factors and soluble CD14 in the inflammatory processes underlying atherosclerosis.

Main Methods:

• Genotyping of TLR-4 and CD14 polymorphisms using Restriction Fragment Length Polymorphism-Polymerase Chain Reaction (RFLP-PCR) on DNA from aortic specimens and blood samples.
• Quantification of plasma soluble CD14 (sCD14) levels via ELISA in patients with CAD and healthy controls.
• Comparison of genetic frequencies and sCD14 levels between CAD patients, individuals with coronary atheromatosis, and healthy controls.

Main Results:

• No significant differences were found for TLR-4 Asp299Gly and Thr399Ile polymorphisms between groups.
• The T allele of the CD14 C260T polymorphism was more frequent in the control group (p=0.05), with the TT genotype associated with healthy individuals (OR 0.25, p=0.0017).
• Plasma sCD14 levels were reduced in CAD patients (mean 1.35 μg/mL) compared to reference values.

Conclusions:

• TLR-4 polymorphisms (Asp299Gly, Thr399Ile) are not associated with CAD.
• A functional polymorphism in CD14 (C260T) shows a statistically significant difference in expression between healthy individuals and those with CAD.
• The CD14 C260T polymorphism may play a role in the susceptibility or protection against Coronary Artery Disease.